SCHEMBL38665689

SCHEMBL38665689

CC1([C@H](NC(=O)c2ccc3cc(F)ccc3c2OCc2ccc(C(F)(F)F)cc2)C(=O)O)COC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 2/20 0.46
▸ PPARD Q03181 4/20 0.36
▸ PPARA Q07869 2/20 0.36
▸ LRRK2 Q5S007 2/20 0.36
▸ KIFC1 Q9BW19 2/20 0.35
▸ MME P08473 1/20 0.35
▸ ACE P12821 1/20 0.35
▸ CPA1 P15085 1/20 0.35
▸ ACE2 Q9BYF1 1/20 0.35
▸ PTPN1 P18031 1/20 0.35
▸ OPRM1 P35372 1/20 0.35
▸ OPRL1 P41146 1/20 0.35
▸ PPARG P37231 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ MAOB P27338 1/20 0.34
▸ SLC6A5 Q9Y345 1/20 0.33
▸ MAOA P21397 1/20 0.33
▸ TRPV1 Q8NER1 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ UGCG Q16739 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23460719 1.00 CXCR2 (0.46) CXCR2PPARDPPARALRRK2KIFC1
SCHEMBL23460717 1.00 CXCR2 (0.46) CXCR2PPARDPPARALRRK2KIFC1
SCHEMBL38146980 0.93 CXCR2 (0.47) CXCR2PPARDPPARALRRK2KIFC1
SCHEMBL23461018 0.93 CXCR2 (0.47) CXCR2PPARDPPARALRRK2KIFC1
SCHEMBL23460875 0.91 CXCR2 (0.46) CXCR2PPARDPPARALRRK2KIFC1
SCHEMBL38146973 0.91 CXCR2 (0.46) CXCR2PPARDPPARALRRK2KIFC1
SCHEMBL23460874 0.91 CXCR2 (0.46) CXCR2PPARDPPARALRRK2KIFC1
SCHEMBL23460872 0.91 OPRM1 (0.37) CXCR2PPARDPPARAOPRM1PPARG
SCHEMBL23460869 0.91 OPRM1 (0.37) CXCR2PPARDPPARAOPRM1PPARG
SCHEMBL38663896 0.91 OPRM1 (0.37) CXCR2PPARDPPARAOPRM1PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630498-B2 Arylamides and methods of use thereof GENZYME CORPORATION (US) 2026-05-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630498-B2 Arylamides and methods of use thereof CFTR, CLIC1, CLCN2 CXCR2 63/4885PPARD 1912/4885PPARA 1336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback